We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.83B
AUM Growth
-$147M
Cap. Flow
+$37.6M
Cap. Flow %
0.48%
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$125M
2
INSM icon
Insmed
INSM
+$125M
3
ALKS icon
Alkermes
ALKS
+$103M
4
BCYC
Bicycle Therapeutics
BCYC
+$101M
5
ALMS
Alumis Inc
ALMS
+$20.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$308M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$55.5M
3
ROIV icon
Roivant Sciences
ROIV
+$50.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$38.2M
5
AKRO
Akero Therapeutics
AKRO
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRLD icon
26
Prelude Therapeutics
PRLD
$529M
$38.6M 0.49%
10,123,824
– –
IDYA icon
27
IDEAYA Biosciences
IDYA
$3.83B
$37.3M 0.48%
1,062,123
– –
CERS icon
28
Cerus
CERS
$566M
$34.3M 0.44%
19,477,339
– –
SERA icon
29
Sera Prognostics
SERA
$84.4M
$32.2M 0.41%
5,434,399
– –
KRYS icon
30
Krystal Biotech
KRYS
$10.3B
$31.2M 0.4%
169,934
– –
CELC icon
31
Celcuity
CELC
$4.58B
$30.7M 0.39%
1,874,978
+322,500
+21% +$5.4M
ROIV icon
32
Roivant Sciences
ROIV
$26.2B
$29.6M 0.38%
2,798,716
-4,615,118
-62% -$50.6M
IGMS
33
DELISTED
IGM Biosciences
IGMS
$28.1M 0.36%
4,090,316
+1,994
+0% +$17.1K
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$28M 0.36%
683,588
-916,412
-57% -$38.2M
AKRO
35
DELISTED
Akero Therapeutics
AKRO
$25.7M 0.33%
1,097,082
-1,616,123
-60% -$34.6M
DYN icon
36
Dyne Therapeutics
DYN
$4.87B
$23.7M 0.3%
672,096
+387,096
+136% +$11.2M
ALMS
37
Alumis Inc
ALMS
$3.13B
$20.8M 0.27%
+1,562,500
New +$20.8M
GLUE icon
38
Monte Rosa Therapeutics
GLUE
$1.22B
$18.4M 0.24%
4,916,095
– –
MRUS
39
DELISTED
Merus
MRUS
$17.8M 0.23%
+300,000
New +$14.5M
NGNE icon
40
Neurogene
NGNE
$773M
$16.6M 0.21%
456,015
– –
TCRX icon
41
TScan Therapeutics
TCRX
$52.8M
$16.3M 0.21%
2,784,792
– –
SANA icon
42
Sana Biotechnology
SANA
$1.17B
$13M 0.17%
2,380,949
– –
IMVT icon
43
Immunovant
IMVT
$9.16B
$12.3M 0.16%
464,718
+39,709
+9% +$1.13M
XNCR icon
44
Xencor
XNCR
$2.07B
$10.3M 0.13%
545,431
– –
NMRA icon
45
Neumora Therapeutics
NMRA
$306M
$10.2M 0.13%
1,034,600
+400,749
+63% +$4.15M
FATE icon
46
Fate Therapeutics
FATE
$279M
$9.83M 0.13%
2,997,772
+1,179,591
+65% +$5.16M
TSVT
47
DELISTED
2seventy bio
TSVT
$9.62M 0.12%
2,497,526
– –
BMEA icon
48
Biomea Fusion
BMEA
$99.3M
$9.49M 0.12%
2,108,949
– –
CLDX icon
49
Celldex Therapeutics
CLDX
$3.17B
$9.17M 0.12%
247,644
– –
TSHA icon
50
Taysha Gene Therapies
TSHA
$1.98B
$8.97M 0.11%
4,004,756
– –
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2024 Portfolio in Review

As of Q2 2024, Julian Baker held 100 positions worth $7.83B, down 1.8% from $7.97B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Julian Baker's Q2 2024 filing shows 11 new, 18 increased, 11 reduced and 5 closed positions. Its largest new stake was Summit Therapeutics: 23,222,222 shares worth $181M. The largest sale was Incyte, an estimated $308M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2024 buy was Summit Therapeutics: 23,222,222 shares worth $181M.
  • Julian Baker added most to Insmed in Q2 2024, an estimated $125M increase.
  • Julian Baker's biggest Q2 2024 reduction was Incyte, cutting an estimated $308M.
  • Julian Baker fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $3.23M.
  • Julian Baker's ten largest holdings make up 76% of its $7.83B portfolio in Q2 2024.
  • Julian Baker opened 11 new positions and closed 5 in Q2 2024.
  • Julian Baker's portfolio value fell 1.8% quarter-over-quarter to $7.83B.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.